Indivior Pharmaceuticals, Inc. Earnings Per Share (Diluted)
Indivior Pharmaceuticals, Inc. (SUPN) reported Earnings Per Share (Diluted) of $0.98 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was $0.98, a 600.00% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was $0.69, a 81.58% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was $0.78, a 382.01% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was $0.33, a 106.25% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2025 was $1.64, a 3180.00% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2024 was $0.05.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2023 was -$0.92.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.98 10-Q · filed 2026-08-03 | $1.67 10-Q · filed 2026-08-03 | $2.45 derived: net income ÷ weighted average shares · filed 2026-08-03 | $2.77 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2026-03-31 | $0.69 10-Q · filed 2026-04-30 | $1.47 derived: net income ÷ weighted average shares · filed 2026-08-03 | $1.80 derived: net income ÷ weighted average shares · filed 2026-08-03 | $1.95 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2025-12-31 | $0.78 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.11 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.26 derived: net income ÷ weighted average shares · filed 2026-08-03 | $1.64 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.33 10-Q · filed 2025-10-30 | $0.47 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.85 10-Q · filed 2025-10-30 | $1.00 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2025-06-30 | $0.14 10-Q · filed 2026-08-03 | $0.52 10-Q · filed 2026-08-03 | $0.68 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.84 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2025-03-31 | $0.38 10-Q · filed 2026-04-30 | $0.53 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.70 derived: net income ÷ weighted average shares · filed 2026-08-03 | -$0.05 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2024-12-31 | $0.16 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.33 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.05 10-K · filed 2026-02-26 | $0.02 10-K · filed 2025-03-03 |
| 2024-09-30 | $0.16 10-Q · filed 2025-10-30 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.11 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | -$0.72 10-Q · filed 2025-07-31 | -$0.27 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $0.45 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | -$0.92 10-K · filed 2026-02-26 | -$0.94 10-K · filed 2025-03-03 | |||
| 2022-12-31 | -$0.30 10-Q · filed 2025-10-30 | -$0.32 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |